Back

Impact of in-hospital initiation of angiotensin receptor-neprilysin inhibition on left ventricular reverse remodeling in acute heart failure: an insight from PREMIER trial

30 August 2025 (11:15 - 12:00)
Organised by: Logo
Congress Presentation Part of: In-hospital care of acute heart failure Ventricular Remodelling ESC Professional Premium Access ESC Congress 2025 European Society of Cardiology

About the speaker

Photo
Assistant Professor Tomonori Takahashi

Tokushima University Hospital, Tokushima (Japan)

7 More presentations in this session

Presentation thumbnail
Levosimendan therapy and mortality predictors in end-stage heart failure patients beyond advanced therapeutic options
Doctor S. Jimenez-Marrero (Barcelona, ES)
Abstract Slides Video
Presentation thumbnail
Prognostic impact of urine output after catecholamine administration in cardiogenic shock due to acute decompensated heart failure
Doctor S. Kawanami (Sakai, JP)
Abstract Slides Video
Presentation thumbnail
Impact and course of albuminuria in acute heart failure according to left or right sided heart failure phenotype
Mr J. Deniz Rosario (Las Palmas de Gran Canaria, ES)
Abstract Slides Video
Presentation thumbnail
Prognostic value of energetic hemodynamics in acute heart failure: beyond conventional measures
Doctor H. Chang (Taipei, TW)
Abstract Slides Video
Presentation thumbnail
Guideline directed medical treatment and comorbidity burden among patients admitted with acute HF decompensation: insights from the HECMOS 2.0
Doctor I. Leontsinis (Athens, GR)
Abstract Slides Video

Access the full session

Session thumbnail
In-hospital care of acute heart failure

The Event

Event poster

ESC Congress 2025

30 August 2025 11:15 CET
You may be interested in
thumbnail
Congress Presentation
Titration of sacubitril/valsartan in acute heart failure
thumbnail
Congress Presentation
Early in-hospital initiation of angiotensin-neprilysin inhibition in Japanese patients with acute heart failure: the investigator-initiated multicenter randomized PREMIER study
thumbnail
Congress Presentation
The positive effect of sacubitril/valsartan therapy on QRS width and QTC interval on electrocardiogram in heart failure patients with reduced ejection fraction

ESC 365 is supported by

novartis Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources